The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Open accessAbstract
Small cell lung cancer (SCLC) is an aggressive malignancy distinct from non–small cell lung cancer (NSCLC) in its metastatic potential and treatment response. Using an integrative proteomic and transcriptomic analysis, we investigated molecular differences contributing to the distinct clinical behavior of SCLCs and NSCLCs. SCLCs showed lower levels of several receptor tyrosine kinases and decreased activation of phosphoinositide 3-kinase (PI3K) and Ras/mitogen-activated protein (MAP)/extracellular signal–regulated kinase (ERK) kinase (MEK) pathways but significantly increased levels of E2F1-regulated factors including enhancer of zeste homolog 2 (EZH2), thymidylate synthase, apoptosis mediators, and DNA repair proteins. In addition, PARP1, a DNA repair protein and E2F1 co-activator, was highly expressed at the mRNA and protein levels in SCLCs. SCLC growth was inhibited by PARP1 and EZH2 knockdown. Furthermore, SCLC was significantly more sensitive to PARP inhibitors than were NSCLCs, and PARP inhibition downregulated key components of the DNA repair machinery and enhanced the efficacy of chemotherapy. Significance: SCLC is a highly lethal cancer with a 5-year survival rate of less than 10%. To date, no molecularly targeted agents have prolonged survival in patients with SCLCs. As a step toward identifying new targets, we systematically profiled SCLCs with a focus on therapeutically relevant signaling pathways. Our data reveal fundamental differences in the patterns of pathway activation in SCLCs and NSCLCs and identify several potential therapeutic targets for SCLCs, including PARP1 and EZH2. On the basis of these results, clinical studies evaluating PARP and EZH2 inhibition, together with chemotherapy or other agents, warrant further investigation. Cancer Discov; 2(9); 798–811. ©2012 AACR. Read the Commentary on this article by Rosell and Wannesson, p. 769. This article is highlighted in the In This Issue feature, p. 753.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,845
Diversity of gene expression in adenocarcinoma of the lung
Garber, M. E., Troyanskaya, O. G., Schluens, K., Petersen, S., Thaesler, Z., Pacyna-Gengelbach, M., van de Rijn, M., Rosen, G. D., Perou, C. M., Whyte, R. I., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241500798 · Cited by 1,298
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
NCBI GEO: archive for functional genomics data sets--10 years on
Barrett, T., Troup, D. B., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1184 · Cited by 1,124
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487
Protein methyltransferases as a target class for drug discovery
Copeland, R. A., Solomon, M. E., & Richon, V. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2974 · Cited by 460
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
Dai, Y., & Grant, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1029 · Cited by 439
Zhou, B.-B. S., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y., Baribaud, F., Mikami, I., Reguart, N., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.024 · Cited by 374
Self-citationCeppi, P., Volante, M., Saviozzi, S., Rapa, I., Novello, S., Cambieri, A., Lo Iacono, M., Cappia, S., Papotti, M., & Scagliotti, G. V. (2006) · Cancer · doi:10.1002/cncr.22208 · Cited by 363
Parkinson, H., Sarkans, U., Kolesnikov, N., Abeygunawardena, N., Burdett, T., Dylag, M., Emam, I., Farne, A., Hastings, E., Holloway, E., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1040 · Cited by 337
Socinski, M. A., Smit, E. F., Lorigan, P., Konduri, K., Reck, M., Szczesna, A., Blakely, J., Serwatowski, P., Karaseva, N. A., Ciuleanu, T., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1548 · Cited by 211
High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors
(1993) · Lung Cancer · doi:10.1016/0169-5002(93)90526-4 · Cited by 207
Delaney, C. A., Wang, L. Z., Kyle, S., White, A. W., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Hostomský, Z., & Newell, D. R. (2000) · PubMed · doi:10.25405/ncl.34597155 · Cited by 205
(1992) · Lung Cancer · doi:10.1016/0169-5002(92)90119-5 · Cited by 196
Kim, Y. H., Girard, L., Giacomini, C. P., Wang, P., Hernandez-Boussard, T., Tibshirani, R., Minna, J. D., & Pollack, J. R. (2006) · Oncogene · doi:10.1038/sj.onc.1208997 · Cited by 182
Self-citationp53 mutations in human lung tumors.
Cw, M., Simon, K., Aslo, A., Kok, K., Yokota, J., Buys, C. H. C. M., Terada, M., & Koeffler, H. P. (1992) · PubMed · Cited by 174
Kaye, F. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205834 · Cited by 153
Verlinden, L., Bempt, I. V., Eelen, G., Drijkoningen, M., Verlinden, I., Marchal, K., Wolf‐Peeters, C. D., Christiaens, M.-R., Michiels, L., Bouillon, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3545 · Cited by 149
Integrated classification of lung tumors and cell lines by expression profiling
Virtanen, C., Ishikawa, Y., Honjoh, D., Kimura, M., Shimane, M., Miyoshi, T., Nomura, H., & Jones, M. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192240599 · Cited by 146
Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
Tarhini, A. A., Kotsakis, A. P., Gooding, W. E., Shuai, Y., Petro, D. P., Friedland, D., Belani, C. P., Đačić, S., & Argiris, A. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0802 · Cited by 137
Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma
Helin, K., Holm, K., Niebuhr, A., Eiberg, H., Tommerup, N., Hougaard, S., Poulsen, H. S., Spang‐Thomsen, M., & Nørgaard, P. H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6933 · Cited by 131
Simbulan-Rosenthal, C. M., Rosenthal, D. S., Luo, R., Samara, R. N., Espinoza, L. A., Hassa, P. O., Hottiger, M. O., & Smulson, M. E. (2003) · Oncogene · doi:10.1038/sj.onc.1206897 · Cited by 115
Huang, C., Liu, D., Nakano, J., Yokomise, H., Ueno, M., Kadota, K., & Wada, H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1539 · Cited by 111
Simbulan-Rosenthal, C. M., Rosenthal, D. S., Boulares, A. H., Hickey, R. J., Malkas, L. H., Coll, J. M., & Smulson, M. E. (1998) · Biochemistry · doi:10.1021/bi9731089 · Cited by 96
Moore, A. M., Einhorn, L. H., Estes, D., Govindan, R., Axelson, J., Vinson, J., Breen, T., Yu, M., & Hanna, N. H. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2005.12.002 · Cited by 95
Tamborini, E., Bonadiman, L., Negri, T., Greco, A., Staurengo, S., Bidoli, P., Pastorino, U., Pierotti, M. A., & Pilotti, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1013 · Cited by 67
Feng, Z., & Zhang, J. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr748 · Cited by 56
Is small cell lung cancer the perfect target for anti-telomerase treatment?
Sarvesvaran, J. (1999) · Carcinogenesis · doi:10.1093/carcin/20.8.1649 · Cited by 54
Cited by
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Self-citationGay, C. M., Stewart, C. A., Park, E. M., Diao, L., Groves, S. M., Heeke, S., Nabet, B. Y., Fujimoto, J., Solis, L. M., Lu, W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.014 · Cited by 962
Self-citationOser, M. G., Niederst, M. J., Sequist, L. V., & Engelman, J. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71180-5 · Cited by 942
Small-cell lung cancer: what we know, what we need to know and the path forward
Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.87 · Cited by 904
Self-citation
Metadata
- Authors
- Byers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y. H., Diao, L., Masrorpour, F., Shen, L., Liu, W., Duchemann, B., Tumula, P., Bhardwaj, V., Welsh, J., Weber, S., Glisson, B. S., Kalhor, N., Wistuba, I. I., Girard, L., Lippman, S. M., Mills, G. B., Coombes, K. R., Weinstein, J. N., Minna, J. D., & Heymach, J. V.
- Venue
- Cancer Discovery
- Published
- 2012-09-01
- Volume
- 2
- Issue
- 9
- Pages
- 798-811
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2098161852
- Cited by
- 557
- References
- 38
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.